N-(2-hydroxypropyl) methacrylamide copolymer-anticancer drugs: Research advances
- Author:
Yong-Guang WANG
1
Author Information
1. Institute of Pharmacology and Toxicology
- Publication Type:Journal Article
- Keywords:
Anticancer drugs;
N-(2-hydroxypropyl) methacrylamide copolymer;
Tumor targeting
- From:
Journal of International Pharmaceutical Research
2010;37(3):174-180
- CountryChina
- Language:Chinese
-
Abstract:
The conjugates of polymer with anticancer drug, due to their enhanced permeability and retention effect can accumulate in solid tumors at a much higher concentration than n normal tissues or organs, which results n higher targeting distribution and lower systemic toxicity. As a macromolecule carrier, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer has many advantages, such as biocompatibility and nonimmunogenicity, so HPMA copolymer-anticancer conjugates has become the focus of large-weight-molecule targeted therapies. Now six HPMA copolymer-anticancer drugs have been evaluated clinically, and many other conjugates are in the stage of preclinical tests. In this paper, research advances in HPMA copolymer-anticancer conjugates are reviewed.
